

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/597,173	07/13/2006	Cheol-Min Kim	P10031US	7115
58986	7590 01/18/2008	•	EXAM	INER
THE RAFFERTY PATENT LAW FIRM 5641 BURKE CENTRE PKWY			OGUNBIYI, OLUWATOSIN A	
SUITE 100 BURKE, VA 22015-2259		ART UNIT	PAPER NUMBER	
Dorden, VIV2	.2013 2237		1645	
		•		
			MAIL DATE	DELIVERY MODE
			01/18/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
	10/597,173	KIM ET AL.				
Office Action Summary	Examiner	Art Unit				
	Oluwatosin Ogunbiyi	1645				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period was reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	the mailing date of this communication.  D (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 13 Ju	<u>ıly 2006</u> .					
,	· · · · · · · · · · · · · · · · · · ·					
·	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) ☐ Claim(s) 1-9 is/are pending in the application. 4a) Of the above claim(s) is/are withdray 5) ☐ Claim(s) is/are allowed. 6) ☐ Claim(s) is/are rejected. 7) ☐ Claim(s) is/are objected to. 8) ☐ Claim(s) 1-9 are subject to restriction and/or el						
Application Papers						
9) The specification is objected to by the Examine 10) The drawing(s) filed onis/ are: a) accomplicated any accomplicated any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 1.	epted or b) objected to by the fidal drawing(s) be held in abeyance. See ion is required if the drawing(s) is obj	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No.  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)  1) Notice of References Cited (PTO-892)  2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Informal F 6) Other:					

10/597,173 Art Unit: 1645

#### **DETAILED ACTION**

Claims 1-9 are pending in the application.

#### **Election/Restrictions**

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- Group I, claim(s) 1-2 and 9 drawn to oligonucleotides for genotyping
   Mycoplasma and Ureaplasma.
- Group II, claim(s) 3-4 and 9 drawn to oligonucleotides for genotyping
   Acholeoplasma strains.
- Group III, claims 5-7 drawn to a microarray comprising more than one oligonucleotide selected from genus-specific and species-specific oligonucleotides for genotyping Mycoplasma and Ureaplasma.
- Group IV, claims 5-7 drawn to a microarray comprising more than one oligonucleotide selected from genus-specific and species-specific oligonucleotides for genotyping Acholeplasma strains.
- Group V, claim(s) 8, drawn to a method for detecting Mycoplasma strains.

10/597,173 Art Unit: 1645

The inventions listed as Groups I -V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The technical feature linking Group I-V is an oligonucleotide.

Groups I lacks unity with Group II -V, because the technical feature of the Groups is anticipated by the art and therefore not "special" within the meaning of PCT Rule 13.2 because it does not provide for a contribution that the claimed invention makes over the art. The first appearing technical feature is an oligonucleotide comprising SEQ ID NO:7. This technical feature is anticipated by Harasawa et al. J. Vet. Med. Sci. 58(3):191-195, 1996. Harasawa et al teach an oligonucleotide that comprises a sequence that is 100 % identical to SEQ ID NO: 7.

# Notice of Possible Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. <u>All</u> claims directed to a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper

10/597,173 Art Unit: 1645

restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

## **Species Election**

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1. The species are as follows:

#### Group I

- A. Oligonucleotide for genus-specific typing: SEQ ID Nos. 7-21.
- B. Oligonucleotide for species-specific typing: SEQ ID Nos. 28-127.

## Group II

- A. Oligonucleotide for genus-specific typing: SEQ ID Nos. 22-27.
- B. Oligonucleotide for species-specific typing: SEQ ID Nos. 128-133.

## Group III

- A. Oligonucleotide for genus-specific typing: SEQ ID Nos. 7-21.
- B. Oligonucleotide for species-specific typing: SEQ ID Nos. 28-127
- C. Probes: DNA,RNA,PNA,LNA and HNA.
- D. Support: slide glass, plastic, membrane, semiconductive chip, silicon and gel.

## Group IV

A. Oligonucleotide for genus-specific typing: SEQ ID Nos. 22-27.

10/597,173 Art Unit: 1645

- B. Oligonucleotide for species-specific typing: SEQ ID Nos. 128-133.
- C. Probes: DNA,RNA,PNA,LNA and HNA.
- D. Support: slide glass, plastic, membrane, semiconductive chip, silicon and gel.

## Group V

- A. Oligonucleotide for genus-specific typing: SEQ ID Nos. 7-21.
- B. Oligonucleotide for species-specific typing: SEQ ID Nos. 28-127

The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: technical feature linking species is not novel and is not defined over the prior art (Harasawa et al as set forth supra).

Applicant is required, in reply to this action, to elect a single species from each category of species listed for the Group of invention elected and to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, there are no generic claim(s). The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

If a generic claim(s) is added and upon the allowance of the generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

10/597,173 Art Unit: 1645

The election of an invention or-species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Oluwatosin Ogunbiyi whose telephone number is 571-272-9939. The examiner can normally be reached on M-F 8:30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Shanon Foley can be reached on 571-272-0898. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

10/597,173 Art Unit: 1645

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Oluwatosin Ogunbiyi

Patent Examiner

Art unit, 1645

SHANON FOLEY
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600